On March 8, 2021 DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, reported that the company will participate in three upcoming investor conferences. Details of the company’s participation are as follows (Press release, DiaMedica, MAR 8, 2021, View Source [SID1234576334]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

33rd Annual Roth Conference
Details: DiaMedica Therapeutics management will deliver a fireside chat and participate in 1-on-1 meetings
Company conference participation date: March 15th, 2021
Oppenheimer’s 31st Annual Healthcare Conference
Details: DiaMedica Therapeutics management will deliver a corporate presentation and participate in 1-on-1 meetings
Company conference participation date: March 16th, 2021
Maxim’s Emerging Growth Conference
Details: DiaMedica Therapeutics management will deliver a corporate presentation and participate in 1-on-1 meetings
Company conference participation date: March 17th, 2021

On March 8, 2021 vTv Therapeutics Inc. (Nasdaq: VTVT) a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for type 1 diabetes and inflammatory diseases, reported its participation in the H.C. Wainwright Global Life Sciences Conference held virtually March 9-10, 2021 (Press release, vTv Therapeutics, MAR 8, 2021, View Source [SID1234576333]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The company will be providing a general company update through a virtual presentation that will be available on demand for conference attendees beginning on March 9, 2021. Company management will also be meeting with members of the investment community during one-on-one virtual meetings.

On March 8, 2021 Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, reported that members of the management team will present during a fireside chat at the H.C. Wainwright Global Life Sciences Conference, being held Mar 9-10, 2021 (Press release, Altimmune, MAR 8, 2021, View Source [SID1234576332]). Also, Altimmune’s Chief Medical Officer, Dr. Scott Harris, will be giving an oral presentation at the 2021 NASH-TAG Conference, being held March 11-13, 2021.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details on the H.C. Wainwright fireside chat presentation are as follows:

Title: H.C. Wainwright Global Life Sciences Conference

Presenters: Vipin Garg, Ph.D., Chief Executive Officer
Scot Roberts, Ph.D., Chief Scientific Officer
Scott Harris, M.D., Chief Medical Officer

Date/Time: March 9, 2021 at 7:00 am ET

A webcast link to the H.C. Wainwright fireside chat presentation will be accessible on the Events section of the Altimmune website.

Details on the NASH-TAG 2021 presentation by Dr. Scott Harris are as follows:

Title: Dual GLP-1 Agonists in the Treatment of Metabolic
& Liver Dysfunction in NASH

Presenter: Scott Harris M.D., Chief Medical Officer

Date/Time: March 13, 2021 at 9:30 pm ET

A copy of the presentation materials will be accessible on the Events section of the Altimmune website.

On March 8, 2021 INmune Bio, Inc. (NASDAQ: INMB) (the "Company" or "INmune"), a clinical-stage immunology company focused on developing treatments that harness a patient’s innate immune system to fight disease, reported that its management team is scheduled to participate in two upcoming virtual investor conferences in March 2021 (Press release, INmune Bio, MAR 8, 2021, View Source [SID1234576312]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

33rd Annual Roth Virtual Conference

Panel Discussion: Therapeutics Against SARS-CoV-2 – Viral Variants Will Not Fade Away
Panel Date: Monday, March 15, 2021
Panel Time: 12:00 PM Eastern Time
Interested parties may register for the panel here

Oppenheimer 31st Annual Healthcare Conference

Presentation Date: Tuesday, March 16, 2021

Presentation Time: 1:10 PM Eastern Time
Interested parties may register for the panel here

Please contact your representative at either Roth or Oppenheimer to schedule a virtual one-on-one meeting with INmune Bio during the respective conference.

On March 8, 2021 Charles River Laboratories International, Inc. (NYSE: CRL) reported that it intends to offer $1 billion aggregate principal amount of senior notes due 2029 and 2031 (the "notes") in an unregistered offering, subject to market conditions (Press release, Charles River Laboratories, MAR 8, 2021, View Source [SID1234576305]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Charles River intends to use the gross proceeds of the offering of the notes to redeem its 5.5% senior notes due 2026 (the "2026 notes"), to fund, along with borrowings under its senior credit facilities, a portion of the purchase price for its proposed acquisition of Cognate BioServices, Inc., and to pay fees and expenses in connection with the offering, the redemption of the 2026 notes, and the amendment of its senior credit facilities.

The notes have not been, and will not be, registered under the Securities Act of 1933, as amended (the "Securities Act"), or under the securities laws of any other jurisdiction. Unless they are registered, the notes may be offered only in transactions that are exempt from registration under the Securities Act and applicable state securities laws. The notes will be offered only to persons reasonably believed to be qualified institutional buyers under Rule 144A under the Securities Act and to non-U.S. persons outside the United States under Regulation S of the Securities Act.

This press release does not constitute an offer to sell or a solicitation of an offer to buy the notes, nor shall there be any sale of the notes in any state or jurisdiction in which such an offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.